Aadi Bioscience Unveils Groundbreaking Clinical Data from PRECISION 1 and AMPECT Trials at SGO Annual Women’s Cancer Meeting

At the Society of Gynecological Oncology (SGO) Annual Meeting 2023, Aadi Bioscience, Inc. (NASDAQ: AADI) presented data from its PRECISION 1 and AMPECT trials that showcased the potential of its precision therapies for genetically-defined cancers with alterations in mTOR pathway genes. Held in Tampa, FL from March 25-28, 2023, the data presented at the SGO Annual Meeting provided a glimpse into the promise of Aadi’s groundbreaking treatments.

We are delighted to share more data on nab-sirolimus from our AMPECT trial and showcase our PRECISION 1 trial at the esteemed SGO 2023. SGO 2023 is the premier medical meeting dedicated to advancing research in gynecologic cancer, making it the perfect platform to present our groundbreaking findings. Loretta Itri, MD., Chief Medical Officer of Aadi Bioscience, emphasizes the importance of this opportunity and looks forward to presenting our study.

The Society of Gynecological Oncology Annual Meeting on Women’s Cancer is a unique opportunity for medical professionals to learn and share their knowledge on treating and caring for women with gynecologic cancer.

Attendees have the chance to explore cutting-edge research and clinical advances through a variety of abstracts and sessions. With a wealth of resources and networking opportunities, this event promises to be a powerful learning experience.

About Aadi Bioscience, Inc.

Aadi is revolutionizing cancer treatments with precision therapies tailored to genetically-defined cancers. Our FDA-approved FYARRO® is a groundbreaking therapy designed to treat adult patients with locally advanced unresectable or metastatic malignant perivascular epithelioid cell tumor (PEComa). By targeting the mTOR pathway, we are dedicated to bringing transformational treatments to those fighting this devastating disease.

Aadi has launched PRECISION 1, a groundbreaking Phase 2 trial for those with mTOR inhibitor-naïve malignant solid tumors harboring TSC1 or TSC2 inactivating alterations. This registration-intended trial is set to revolutionize the way people with these diseases are treated and provide a much-needed alternative for those seeking relief.

Leave a Comment